Key Players
Competitive Landscape
The radiopharmaceutical theranostics market is characterized by presence of therapeutic product manufacturers, diagnostic imaging companies, isotope suppliers and clinical-stage developers. Novartis has PSMA and SSTR therapies along with regional manufacturing facilities. Telix and Lantheus are focusing on PSMA imaging products, while Curium combines diagnostic products with SSTR treatment. ITM supplies lutetium-177 and is also developing therapeutic radiopharmaceuticals. Some of the key players are expanding manufacturing, product development and distribution activities in order to cater the growing demand and increase market share.
Investment in radiopharmaceutical manufacturing is one of the prominent trends in the market. In November 2025, Novartis opened a 10,000-square-foot California radioligand facility for increasing regional dose supply. Curium reported Phase 3 ECLIPSE dosimetry from 26 patients in February 2026.[33] ITM presented COMPETE dosimetry in June 2026 using 207 kidney datasets and 154 tumor datasets.[34]. Manufacturing facilities located nearer to treatment centers can reduce delivery distance, whereas dosing evidence supports further product evaluation. These factors are anticipated to support competition in the radiopharmaceutical theranostics market.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| May 2026: Telix announced collaborations to evaluate PSMA PET in image-guided prostate treatment workflows. | Treatment planning needs target-specific imaging. | Imaging is moving into procedural pathways. | Generate evidence for selection and follow-up. |
| February 2026: Curium reported Phase 3 ECLIPSE dosimetry from 26 patients. | PSMA therapy needs a supported dosing plan. | Programs are adding prospective dose analysis. | Support evaluation of up to six cycles. |
| November 2025: Novartis opened a 10,000-square-foot California RLT facility. | Time-sensitive doses require regional production. | Manufacturing is moving nearer to treatment sites. | Add western U.S. supply after site approval. |
Other prominent participants are developing radiopharmaceuticals through actinium, copper and other isotope routes. Bristol Myers Squibb Company and AstraZeneca plc are focusing on actinium-based therapeutic platforms, whereas Clarity Pharmaceuticals Ltd. is evaluating a copper-based PSMA platform. In August 2026, Clarity reported interim findings for copper-67 SAR-bisPSMA.[29]. Development of new isotopes and molecular targets can increase treatment options beyond the currently approved products. Increasing research and development activities is expected to create growth opportunities in the market.
Source: Future Market Insights, Radiopharmaceutical Theranostics Market Report, 2026-2036.
Product eligibility and availability of a qualified treatment route together supports regular radiopharmaceutical use.
How do the profiled companies differ in evidenced market positioning?
Novartis AG offers PSMA- and SSTR-directed therapies, whereas Bayer AG offers Xofigo for bone-metastatic prostate cancer and it is not a PSMA radioligand. Lantheus Holdings, Inc. and Telix Pharmaceuticals Limited have PSMA imaging products, while their therapeutic products are at different stages. Thus, companies are positioned on the basis of approved therapy, diagnostic imaging, isotope supply and clinical development rather than one common product category.
What should buyers evaluate before approving a supplier?
Hospitals generally evaluates approved indication, required companion imaging, manufacturing authorization, dose delivery and receiving-site support before selecting a radiopharmaceutical supplier. Availability of isotope, cancellation conditions and radiation-safety documents also affects regular product purchasing. Suppliers offering dependable dose delivery and site support are expected to gain preference among treatment centers.
Which product and application distinctions matter within the company set?
Curium’s BEXLUTRY and Lantheus Holdings, Inc.’s BRAVNETSA are used for SSTR-positive GEP-NETs, however, the cited announcements describe different U.S. regulatory routes. AstraZeneca plc is developing FPI-2265 as an actinium-based PSMA program. Clarity Pharmaceuticals Ltd. is evaluating copper-67 therapy with copper-64 imaging for patient selection. Copper-64 imaging is included as the matched platform context and is not counted in the named diagnostic isotope revenue.
What does the evidence establish about the companies’ geographic reach?
Novartis AG has product activity in the USA, Japan, Europe and Australia. Telix Pharmaceuticals Limited has commercial diagnostic products across several countries, however, this does not mean similar access for its investigational therapies. Eli Lilly and Company has radioligand manufacturing and research capability through POINT Biopharma. ITM Isotope Technologies Munich SE links German operations with French irradiation capacity through its collaboration with ILL. Presence of product approval, manufacturing and distribution in different countries is expected to support geographic expansion of these companies.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Novartis AG | Integrated therapeutic and manufacturing company | November 2025: Opened a 10,000-square-foot California RLT facility, pending approval as an additional supply point. |
| Bayer AG | Approved radium-223 therapy owner | February 2026: Reported PEACE-3 overall-survival findings for Xofigo with enzalutamide. |
| Eli Lilly and Company | Clinical-stage radioligand platform owner | POINT Biopharma provides radioligand development and manufacturing capabilities. |
| Bristol Myers Squibb Company | Actinium-based therapeutic developer | RayzeBio adds an actinium radiopharmaceutical platform and manufacturing capability. |
| AstraZeneca plc | Actinium radioconjugate developer | Fusion adds the investigational FPI-2265 PSMA program and radioconjugate platform. |
| Lantheus Holdings, Inc. | PSMA imaging and SSTR therapy company | September 2026: Reported final FDA approval of BRAVNETSA for SSTR-positive GEP-NETs. |
| Telix Pharmaceuticals Limited | Diagnostic network and therapeutic developer | May 2026: Announced PSMA PET collaborations for image-guided prostate procedures. |
| Curium | Integrated diagnostic and therapeutic supplier | February 2026: Reported ECLIPSE dosimetry supporting evaluation of six treatment cycles. |
| ITM Isotope Technologies Munich SE | Isotope producer and therapeutic developer | June 2026: Presented single-timepoint dosimetry analysis from COMPETE. |
| Clarity Pharmaceuticals Ltd. | Copper-based theranostic developer | August 2026: Reported interim SECuRE findings for copper-67 SAR-bisPSMA. |
Research Methodology
The competitive assessment includes companies having approved radiopharmaceutical products, clinical-stage programs, isotope supply, manufacturing or diagnostic distribution. Information is collected from regulators, official company announcements, product information, filings and technical publications. Company developments are included where they supports product approval, manufacturing capacity, supply agreement, partnership or clinical progress. Announced capacity is kept separate from approved commercial supply and company inclusion does not indicate revenue rank or clinical superiority.
